Aprotinin combined with nitric oxide and prostaglandin E1 protects the canine kidney from cardiopulmonary bypass-induced injury

European Journal of Cardio-thoracic Surgery

Volumn 38, Issue 1, 2010, Pages 98-103

  Du, Lei ^a   Zhou, Jing ^a   Tang, Jiali ^a   An, Qi ^a   Lin, Ke ^a   Wu, Xiaodong ^a   Tao, Kaiyu ^a   Liu, Jin ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Cardiac surgery; Cardiopulmonary bypass; Kidney; Renal failure

Indexed keywords

APROTININ; CD11B ANTIGEN; CREATININE; ELASTASE; MYELOPEROXIDASE; NITRIC OXIDE; PROSTAGLANDIN E1; PROTHROMBIN; THROMBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOPULMONARY BYPASS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DOG; ENZYME ACTIVITY; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY INJURY; LEUKOCYTE ACTIVATION; NEUTROPHIL COUNT; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT;

ACUTE KIDNEY INJURY; ALPROSTADIL; ANIMALS; APROTININ; CARDIOPULMONARY BYPASS; CREATININE; DOGS; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; HEMOSTATICS; MALE; NEUTROPHIL ACTIVATION; NITRIC OXIDE; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; VASODILATOR AGENTS;

EID: 77953284899     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2010.01.025     Document Type: Article

References (25)

1. Unsworth-White M.J., Herriot A., Valencia O., Poloniecki J., Smith E.E., Murday A.J., Parker D.J., and Treasure T. Resternotomy for bleeding after cardiac operation: a marker for increased morbidity and mortality. Ann Thorac Surg 59 (1995) 664-667
2. Dunning J., Versteegh M., Fabbri A., Pavie A., Kolh P., Lockowandt U., Nashef S.A., and EACTS Audit and Guidelines Committee. Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardiothorac Surg 34 (2008) 73-92
3. Brown J.R., Birkmeyer N.J., and O'Connor G.T. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 115 (2007) 2801-2813
4. Mangano D.T., Tudor I.C., and Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 354 (2006) 353-365
5. Mangano D.T., Miao Y., Vuylsteke A., Tudor I.C., Juneja R., Filipescu D., Hoeft A., Fontes M.L., Hillel Z., Ott E., Titov T., Dietzel C., Levin J., and Investigators of The Multicenter Study of Perioperative Ischemia Research Group. Ischemia Research and Education Foundation. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 297 (2007) 471-479
6. Fergusson D.A., Hebert P.C., Mazer C.D., Fremes S., MacAdams C., Murkin J.M., Teoh K., Duke P.C., Arellano R., Blajchman M.A., Bussières J.S., Côté D., Karski J., Martineau R., Robblee J.A., Rodger M., Wells G., Clinch J., Pretorius R., and BART Investigators. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 358 (2008) 2319-2331
7. Alderman E.L., Levy J.H., Rich J.B., Nili M., Vidne B., Schaff H., Uretzky G., Pettersson G., Thiis J.J., Hantler C.B., Chaitman B., and Nadel A. Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg 116 (1998) 716-730
8. Havel M.P., Griesmacher A., Weigel G., Owen A., Simon P., Müller M.M., and Wolner E. Aprotinin decreases release of 6-keto-prostaglandin F1 alpha and increases release of thromboxane B2 in cultured human umbilical vein endothelial cells. J Thorac Cardiovasc Surg 104 (1992) 654-658
9. Samama C.M., Mazoyer E., Bruneval P., Ciostek P., Bonnin P., Bonneau M., Roussi J., Bailliart O., Pignaud G., and Viars P. Aprotinin could promote arterial thrombosis in pigs: a prospective randomized, blind study. Thromb Haemost 71 (1994) 663-669
10. Hill G.E., Taylor J.A., and Robbins R.A. Differing effects of aprotinin and epsilon-aminocaproic acid on cytokine-induced inducible nitric oxide synthase expression. Ann Thorac Surg 63 (1997) 74-77
11. Esmon C.T. The interactions between inflammation and coagulation. Br J Haematol 131 (2005) 417-430
12. Vio C.P., Oestreicher E., Olavarria V., Velarde V., Mayfield R.K., and Jaffa A.A. Cellular distribution of exogenous aprotinin in the rat kidney. Biol Chem 379 (1998) 1271-1277
13. Beller F.K., Mitchell P.S., and Gorstein F. Fibrin deposition in the ribbit kidney produced by protease inhibitors. Thromb Diath Haemorrh 17 (1967) 427-439
14. Schweizer A., Hohn L., Morel D.R., Kalangos A., and Licker M. Aprotinin does not impair renal haemodynamics and function after cardiac surgery. Br J Anaesth 84 (2000) 16-22
15. Lindvall G., Sartipy U., Ivert T., and van der L.J. Aprotinin is not associated with postoperative renal impairment after primary coronary surgery. Ann Thorac Surg 86 (2008) 13-19
16. Maslow A.D., Chaudrey A., Bert A., Schwartz C., and Singh A. Perioperative renal outcome in cardiac surgical patients with preoperative renal dysfunction: aprotinin versus epsilon aminocaproic acid. J Cardiothorac Vasc Anesth 22 (2008) 6-15
17. Furnary A.P., Wu Y., Hiratzka L.F., Grunkemeier G.L., and Page III U.S. Aprotinin does not increase the risk of renal failure in cardiac surgery patients. Circulation 116 11 Suppl. (2007) I127-I133
18. Edmunds L.H. Cardiopulmonary bypass after 50 years. N Engl J Med 351 (2004) 1603-1606
19. Levy J.H., and Tanaka K.A. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 75 (2003) S715-S720
20. Boyle Jr. E.M., Pohlman T.H., Johnson M.C., and Verrier E.D. Endothelial cell injury in cardiovascular surgery: the systemic inflammatory response. Ann Thorac Surg 63 (1997) 277-284
21. Greilich P.E., Brouse C.F., Rinder C.S., Smith B.R., Sandoval B.A., Rinder H.M., Eberhart R.C., and Jessen M.E. Effects of epsilon-aminocaproic acid and aprotinin on leukocyte-platelet adhesion in patients undergoing cardiac surgery. Anesthesiology 100 (2004) 225-233
22. Shimoyama T., Tabuchi N., Kojima K., Akamatsu H., Arai H., Tanaka H., and Sunamori M. Aprotinin attenuated ischemia-reperfusion injury in an isolated rat lung model after 18-hours preservation. Eur J Cardiothorac Surg 28 (2005) 581-587
23. McLaughlin J.N., Patterson M.M., and Malik A.B. Protease-activated receptor-3 (PAR3) regulates PAR1 signaling by receptor dimerization. Proc Natl Acad Sci U S A 104 (2007) 5662-5667
24. Houle S., Papez M.D., Ferazzini M., Hollenberg M.D., and Vergnolle N. Neutrophils and the kallikrein-kinin system in proteinase-activated receptor 4-mediated inflammation in rodents. Br J Pharmacol 146 (2005) 670-678
25. Day J.R., Taylor K.M., Lidington E.A., Mason J.C., Haskard D.O., Randi A.M., and Landis R.C. Aprotinin inhibits proinflammatory activation of endothelial cells by thrombin through the protease-activated receptor 1. J Thorac Cardiovasc Surg 131 (2006) 21-27